Clinical trials: Gout, open to volunteers
Gout Initiating Urate-loweringUrate-lowering Therapy
The Remote Monitoring of Gout Study
The goal of this clinical trial is to: compare a new digital self-management treatment strategy to usual care, for patients with gout receiving urate lowering therapy in specialist healthcare.
- Trial name
- ReMonit Gout (NCT06822933)
- Testing
- Urika, Nurse-led follow-up with telephone consultations.
- Where
- Norway
- Volunteers
- 168 people
- Sponsor
- Diakonhjemmet Hospital
Gout Disease
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including…
- Trial name
- NCT07889284
- Testing
- Combined metabolic activators, Collagen and maltodextrin
- Where
- 12 sites in Turkey (Türkiye)
- Volunteers
- 336 people
- Sponsor
- ScandiBio Therapeutics AB
Gout, Gouty Arthritis
Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete.
- Trial name
- Pham-UP (NCT06887452)
- Testing
- Pharmacist-Led
- Where
- 5 sites in United States
- Volunteers
- 310 people
- Sponsor
- VA Office of Research and Development
Uncontrolled Gout
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus pegloticase 8 mg intravenously (IV) every two weeks with MTX on the response…
- Trial name
- NCT07388498
- Testing
- Pegloticase, Methotrexate
- Where
- 75 sites in United States, Puerto Rico
- Volunteers
- 270 people
- Sponsor
- Amgen
Gout
Metformin in Safety and Efficacy in Gouty Patients
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints.
- Trial name
- NCT06924658
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Mostafa Bahaa
Gout
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the…
- Trial name
- RELEASE (NCT07280156)
- Testing
- PRX-115, Methotrexate (MTX)
- Where
- 35 sites in United States, Georgia and 1 more
- Volunteers
- 150 people
- Sponsor
- Protalix
Gout
A Study of Dotinurad Versus Allopurinol in Participants With Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
- Trial name
- NCT07089875
- Testing
- Allopurinol, Dotinurad
- Where
- 115 sites in United States, Poland and 1 more
- Volunteers
- 500 people
- Sponsor
- Crystalys Therapeutics
Tophaceous Gout
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
- Trial name
- NCT07089888
- Testing
- Allopurinol, Dotinurad
- Where
- 95 sites in United States
- Volunteers
- 250 people
- Sponsor
- Crystalys Therapeutics
Gout
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
- Trial name
- NCT07535034
- Testing
- Dotinurad
- Where
- 41 sites in United States
- Volunteers
- 90 people
- Sponsor
- Crystalys Therapeutics
Gout Disease, Gout
Evaluation of the Impact of Dietary Education and Intervention on Gout Patients Receiving Urate-Lowering Therapy
The goal of this interventional study is to learn whether dietary education and intervention can reduce blood uric acid levels in patients with gout.
- Trial name
- NCT07834840
- Testing
- DASH Diet, Low-Uric acid Diet
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Sung Keon Cho
Gout, Obesity (BMI>30)
Mazdutide for Weight Management and Gout in Adults With Obesity
This is a single-arm, open-label, pre-post controlled study to evaluate the effect of Mazdutide on the annualized flare rate (AFR) in adults with obesity and gout.
- Conditions
- Gout, Obesity (BMI>30), Hyperuricemia, Metabolic Syndrome
- Trial name
- NCT07824895
- Testing
- Mazdutide
- Volunteers
- 30 people
- Sponsor
- Hongwei Jiang
Gout, Coronary Atheroma
The Correlation Between Sodium Urate (MSU) Deposition and Coronary Atherosclerosis in Patients With Foot Gout
This observational study aims to evaluate the association between sodium urate deposition volume and coronary atherosclerotic plaques in patients with foot gout using dual-energy CT (DECT) and coronary CTA.
- Trial name
- NCT07784049
- Testing
- DECT;CCTA
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Type2Diabetes, Hypertension
Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity
The purpose of this study was to explore the effectiveness of the "Digital Care Community Common Good" program in improving disease control indicators, self-management abilities, depression, and quality of life among patients…
- Conditions
- Type2Diabetes, Hypertension, Dyslipidemia, CKD
- Trial name
- NCT07310849
- Testing
- Digital Care Community Common Good Program, Usual Care
- Where
- Taiwan
- Volunteers
- 169 people
- Sponsor
- Chang Gung University of Science and Technology
AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
Background: Pyrimidine and purine metabolism disorders (DPPMs) affect how the body metabolizes chemicals called pyrimidines and purines.
- Conditions
- AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of
- Trial name
- NCT06092346
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Gout and Hyperuricemia
SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors [SGLT2i] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate [SU] levels of gout…
- Trial name
- SAVE-Care (NCT06674109)
- Testing
- Empagliflozin 10 mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Refractory Gout
A Study of IN026 in Participants With Refractory Gout
The goal of this clinical study is to learn if IN026 Injection is safe and works to lower uric acid levels in adults with refractory gout (gout that does not respond well to standard treatments).
- Trial name
- NCT07587684
- Testing
- IN026 Injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gout Arthritis
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
- Trial name
- NCT07708181
- Testing
- SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W
- Volunteers
- 200 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Gout
The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time
To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad…
- Trial name
- NCT07661030
- Testing
- Dotinurad, colchicine, etoricoxib
- Volunteers
- 142 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Rheumatoid Arthritis (RA), Gouty Arthritis (GA)
Musculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis
Rheumatoid arthritis (RA) and gouty arthritis (GA) are two common forms of joint inflammation that can present with very similar physical symptoms, making them difficult to tell apart early in the disease process.
- Conditions
- Rheumatoid Arthritis (RA), Gouty Arthritis (GA), Gout, Inflammatory Arthritis
- Trial name
- NCT07657156
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hyperuricemia With or Without Gout
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects
The primary objective of this study is to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of ascending single orally administered doses of F-02-2-Na in adult subjects (to include the Mass Balance) \& multiple…
- Trial name
- NCT07324434
- Testing
- F-02-2-Na Tablet (0.5 mg), F-02-2-Na Tablet (5 mg), F-02-2-Na Tablet (10 mg)
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.